Cargando…

Foreword to the first special collection: Addressing the invisible iatrogenic epidemic: the role of deprescribing in polypharmacy and inappropriate medication use

Detalles Bibliográficos
Autores principales:	Mangin, Dee, Garfinkel, Doron
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2019
Materias:	The Role of De-Prescribing in Polypharmacy and Inappropriate Medication Use
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804352/ https://www.ncbi.nlm.nih.gov/pubmed/31673327 http://dx.doi.org/10.1177/2042098619883156

Ejemplares similares

Teaching physicians the GPGP method promotes deprescribing in both inpatient and outpatient settings
por: Bilek, Aaron Jason, et al.
Publicado: (2019)

Patients’ attitudes toward deprescribing and their experiences communicating with clinicians and pharmacists
por: Lukacena, Kaylee M., et al.
Publicado: (2022)

A pilot cohort study of deprescribing for nursing home patients acutely admitted to hospital
por: Russell, Patrick, et al.
Publicado: (2019)

Education around medication review and deprescribing: a survey of medical and pharmacy students’ perspectives
por: Poots, Alan J., et al.
Publicado: (2020)

Impact of deprescribing dual-purpose medications on patient-related outcomes for older adults near end-of-life: a systematic review and meta-analysis
por: Shrestha, Shakti, et al.
Publicado: (2021)

Prevalence and global trends of polypharmacy among people living with HIV: a systematic review and meta-analysis
por: Danjuma, Mohammed I., et al.
Publicado: (2022)

Anticholinergic burden in middle-aged women and recurrent falls in later life: findings from the Aberdeen prospective osteoporosis screening study (APOSS)
por: Neal, Samuel R., et al.
Publicado: (2020)

Prescribing cascades in persons with Alzheimer’s disease: engaging patients, caregivers, and providers in a qualitative evaluation of print educational materials
por: Bloomstone, Sarah, et al.
Publicado: (2020)

The impact of medication review with version 2 STOPP (Screening Tool of Older Person’s Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment) criteria in a French nursing home: a 3-month follow-up study
por: Gaubert-Dahan, Marie-Line, et al.
Publicado: (2019)

Applicability of EU(7)-PIM criteria in cross-national studies in European countries
por: Fialová, Daniela, et al.
Publicado: (2019)

When is antidepressant polypharmacy appropriate in the treatment of depression?
por: SI, Tianmei, et al.
Publicado: (2014)

Evaluation of antidepressant polypharmacy and other interventions for treatment-resistant depression
por: PENG, Daihui, et al.
Publicado: (2014)

Provide optimized antidepressant monotherapy with multiple drugs before considering antidepressant polypharmacy
por: SAAH, Tammy, et al.
Publicado: (2014)

International Group for Reducing Inappropriate Medication Use & Polypharmacy (IGRIMUP): Position Statement and 10 Recommendations for Action
por: Mangin, Dee, et al.
Publicado: (2018)

Socio-demographic differences in polypharmacy and potentially inappropriate drug use among older people with different care needs and in care settings in Stockholm, Sweden
por: Doheny, Megan, et al.
Publicado: (2021)

Deprescribing anticholinergic and sedative medicines: protocol for a Feasibility Trial (DEFEAT-polypharmacy) in residential aged care facilities
por: Ailabouni, Nagham, et al.
Publicado: (2017)

Deprescribing to reduce polypharmacy: study protocol for a randomised controlled trial assessing deprescribing of anticholinergic and sedative drugs in a cohort of frail older people living in the community
por: Bergler, Ulrich, et al.
Publicado: (2021)

Deprescribing for all: a narrative review identifying inappropriate polypharmacy for all ages in hospital settings
por: Elbeddini, Ali, et al.
Publicado: (2021)

Rucaparib and Niraparib in Advanced Ovarian Cancer
por: Redelico, Tyler
Publicado: (2019)

Alpelisib: A Novel Therapy for Patients With PIK3CA-Mutated Metastatic Breast Cancer
por: Wilhoit, Tori, et al.
Publicado: (2020)

Polatuzumab Vedotin for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Transplant-Ineligible Patients
por: Douglas, Melanie
Publicado: (2020)

Letermovir for Cytomegalovirus Prevention in Patients Undergoing Hematopoietic Cell Transplantation
por: Daniels, Kori, et al.
Publicado: (2019)

A Review of PI3K Inhibitors in B-Cell Malignancies
por: Cannon, Laura, et al.
Publicado: (2019)

Mogamulizumab-kpkc: A Novel Therapy for the Treatment of Cutaneous T-Cell Lymphoma
por: Watson, Sutton, et al.
Publicado: (2019)

Axicabtagene Ciloleucel: The First FDA-Approved CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
por: King, Amber C., et al.
Publicado: (2019)

Gilteritinib: A Novel FLT3 Inhibitor for Relapsed/Refractory Acute Myeloid Leukemia
por: Marjoncu, Dennis, et al.
Publicado: (2020)

Ribociclib and Abemaciclib: CDK4/6 Inhibitors for the Treatment of Hormone Receptor–Positive Metastatic Breast Cancer
por: Byers, Kristina F.
Publicado: (2021)

Ivosidenib: IDH1 Inhibitor for the Treatment of Acute Myeloid Leukemia
por: Merchant, Shelby L., et al.
Publicado: (2019)

Apalutamide for the Treatment of Nonmetastatic Castration-Resistant Prostate Cancer
por: Patel, Urvi J., et al.
Publicado: (2019)

Caplacizumab for Acute Thrombotic Thrombocytopenic Purpura
por: Katsivalis, Katherine V., et al.
Publicado: (2021)

Pegfilgrastim Biosimilars: Where Are We Now?
por: Selby, Christopher, et al.
Publicado: (2021)

Sacituzumab Govitecan for Treatment of Refractory Triple-Negative Metastatic Breast Cancer
por: Fleming, Patrick J., et al.
Publicado: (2021)

Safety around medicines for eye care
por: Khatun, Alaya, et al.
Publicado: (2021)

Belantamab Mafodotin-blmf: A Novel Antibody-Drug Conjugate for Treatment of Patients With Relapsed/Refractory Multiple Myeloma
por: Ketchum, Emily Behren, et al.
Publicado: (2022)

Tazemetostat: EZH2 Inhibitor
por: Straining, Rachael, et al.
Publicado: (2022)

Glasdegib: A Novel Hedgehog Pathway Inhibitor for Acute Myeloid Leukemia
por: Thompson, Daniel L., et al.
Publicado: (2020)

Advancements in Therapy for Bladder Cancer: Enfortumab Vedotin
por: Hanna, Kirollos S.
Publicado: (2020)

A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies
por: Moore, Donald C., et al.
Publicado: (2021)

Voxelotor: A Hemoglobin S Polymerization Inhibitor for the Treatment of Sickle Cell Disease
por: Yenamandra, Avani, et al.
Publicado: (2020)

Encorafenib and Binimetinib Combination Therapy in Metastatic Melanoma
por: Davis, Jessica, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_2ls99b1506b5nmbg4n1a5qc9t6